Share these talks and lectures with your colleagues
Invite colleaguesWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo talk
This is a limited length demo talk; you may
login
or review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Health concerns in the 20th and 21st centuries
- Different viral infections worldwide
- Current treatments
- Drug development considerations for antivirals
- Innate immune response
- Different pathogen recognition receptors
- IFN influences on immune response
- High conservation degree in IFNalpha subtypes
- IFN subtypes exhibit variable antiviral potency
- Type I IFN signaling
- Global outbreak of SARS
- Why so virulent?
- A mouse model of SARS CoV
- Type I IFN expression profile in infected mice
- IFN-beta protects A/J mice from MHV-1 infection
- Inhibition of SARS CoV by IFN
- Representative chest X-rays in SARS patients
- Interferon effect on lung pathology
- O2 saturation over time
- Interferon prevents HIV spread
- IFN inhibits HIV infection
- Coxsackievirus B3
- IFN gene expression in CVB3 infected mice
- IFN-beta in patients with cardiomyopathy
- Influenza
- Human lung organ model for influenza infection
- IFN alfacon-1 inhibits H5N1 replication in lung
- Swain flu
- IFN treatment inhibits A/WSN/33 H1N1 infection
- IFN-alpha treatment inhibits influenza replication
- IFN inhibits influenza replication
- Post infection IFN alfacon-1 inhibits influenza
- IFN inhibits pandemic H1N1 replication
- A pilot study
- IFNs exhibit different affinities for IFNAR
- 3 amino acid clusters residues influence activity
- IFN alfacon-1
- IFN-alpha-2 interaction with receptor
- Receptor affinity
- In silico modeling
- Strategy for design of nonpeptide mimetics
- Acknowledgements
Topics Covered
- Emerging and re-emerging virus infections globally
- Time lag before a new vaccine is available during a pandemic
- Antivirals that are pathogen specific lead to viral resistance
- Broad spectrum antivirals needed
- Interferons -alpha -beta are produced in response to all virus infections
- Every cell/tissue will respond to interferon
- Widespread application for all virus infections
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Fish, E. (2011, December 5). Interferons as antivirals: translating basic research into clinical application [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 15, 2019, from https://hstalks.com/bs/2154/.Publication History
Financial Disclosures
- Prof. Eleanor Fish has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Interferons as antivirals: translating basic research into clinical application
Published on December 5, 2011
45 min
Other Talks in the Series: Cytokines
Hide